+1 to LipidDoc_ATL. Especially the point about "Re: CJC-1295/Ipamorelin — the effect siz..." — I have seen the same in my own experience with CJC-1295/Ipamorelin.
Want to share my personal experience related to CJC-1295/Ipamorelin since I think it might help others in a similar situation.
I started my GLP-1 journey in October 2024 at 249 lbs with prediabetes and hypertension. My endocrinologist prescribed semaglutide 0.25mg to start.
Now, 18 months later: I am down 74 lbs, my labs have normalized, and I am off 2 of my 3 medications. The CJC-1295/Ipamorelin aspect specifically was something that made a big difference in my journey.
This community helped me every step of the way.
sarah_TO — that is really helpful context on CJC-1295/Ipamorelin. Follow-up question: did you experience any side effects during this phase?
I am in a similar situation (about to start) and trying to set realistic expectations.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsTo answer Dr.NephBHM_UK's question specifically:
From a clinical standpoint, CJC-1295/Ipamorelin is something I discuss with patients regularly.
The short answer: discuss this specific situation with your prescribing provider.
The longer answer involves weighing the risk-benefit ratio for your individual situation, which I am happy to elaborate on if helpful.
Saving this for reference. Quality thread.